NCT06615557进行中（未招募）3 期
US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-4)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 238
- 试验地点
- 27
- 主要终点
- Subjective Units of Distress Scale (SUDS)
研究概览
简要总结
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PALISADE-4 and choose to enter the distinct open-label extension phase of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent provided prior to conducting any study-specific assessment.
- •Male and female adults, 18 through 65 years of age, inclusive.
- •Current diagnosis of SAD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, and confirmed by the Mini-International Neuropsychiatric Interview (MINI).
- •Clinician-rated Liebowitz Social Anxiety Score (LSAS) total score ≥70 at Screening (Visit 1).
- •Clinician-rated Hamilton Depression Rating Scale (HAM-D) (17-items) total score <
- •Female subjects of childbearing potential must be able to commit to the consistent and correct use of an effective method of birth control throughout the study
- •Subjects must have normal olfactory function
排除标准
- •Any history of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, psychosis, anorexia or bulimia, premenstrual dysphoric disorder, autism spectrum disorder, or obsessive-compulsive disorder.
- •Any other current principal or personality disorder (previously known as Axis I or Axis II disorders), except for specific phobias or generalized anxiety disorder, provided that these are not the primary diagnosis.
- •Subjects who meet criteria for moderate or severe alcohol use disorder within the 1 year prior to study entry, or any use of illicit substances or tetrahydrocannabinol ("THC") within 2 months prior to study entry.
- •In the opinion of the investigator, the subject has a significant risk for suicidal behavior during the course of their participation in the study, or the subject is considered to be an imminent danger to themself or others.
- •Clinically significant nasal pathology or history of significant nasal trauma, nasal surgery, total anosmia, or nasal septum perforation that may have damaged the nasal chemosensory epithelium.
- •Two or more documented failed adequate treatment trials with a registered medication approved for SAD.
- •Currently receiving cognitive-behavioral therapy (CBT), exposure therapy, or acceptance and commitment therapy.
- •Subjects taking psychotropic medications within 30 days before Visit
- •Use of any over-the-counter product, prescription product, off-label treatment, cannabidiol ("CBD"), or herbal preparation for treatment of the symptoms of anxiety or social anxiety within 30 days before Visit
- •Prior participation in a clinical trial involving fasedienol.
- •Participation in any other clinical trial within the last 30 days or during the course of the current trial.
- •Subjects with a positive urine drug screen.
- •Women who have a positive urine pregnancy test.
- •Women who are currently breastfeeding are not eligible unless they are willing to stop breastfeeding for the duration of the study.
- •Subjects who have tested positive and/or have exhibited symptoms consistent with SARS-CoV-2 infection during the 4 weeks prior to Screening (Visit 1).
- •Any clinically significant medical history or findings as determined by the Investigator that could interfere with the objectives of the study or put the participant at risk.
研究组 & 干预措施
Placebo Nasal Spray
Experimental
干预措施: Placebo Nasal Spray (Drug)
Fasedienol Nasal Spray
Experimental
干预措施: Fasedienol Nasal Spray (Drug)
结局指标
主要结局
Subjective Units of Distress Scale (SUDS)
时间窗: 7 days (Visit 2 to Visit 3)
The SUDS is a patient self-rated scale that is scored in the range of 0 to 100 (operationalized for participants in this study as 0=totally relaxed or no anxiety and 100=highest distress or anxiety ever felt).
次要结局
- Global Impression Scale of Improvement (CGI-I)(7 days (Visit 2 to Visit 3))
- Patient Global Impression of Change (PGI-C)(7 days (Visit 2 to Visit 3))
研究者
研究点 (27)
Loading locations...
相似试验
进行中（未招募）
3 期
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)Social Anxiety DisorderNCT06358651VistaGen Therapeutics, Inc.238
终止
3 期
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2Social Anxiety DisorderNCT05011396VistaGen Therapeutics, Inc.228
已完成
3 期
PH94B Nasal Spray for Anxiety Induced by a Public Speaking ChallengeSocial Anxiety DisorderNCT04754802VistaGen Therapeutics, Inc.224
已完成
3 期
Efficacy and Safety of Injectable Association of Dexamethasone, Dipyrone and Hydrocobalamin in Lumbar Sciatic PainLumbar Sciatic PainNCT01147289Eurofarma Laboratorios S.A.280
撤回
3 期
A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)Major Depressive Disorder (MDD)NCT06735079MGGM LLC146